Shire shells out $2.6B for New River Pharmaceuticals
DEALS |
|||
WHO |
WITH |
WHAT |
SCOOP |
Shire |
New River Pharmaceuticals |
$2.6B buyout |
The deal gives Shire the ADHD drug Vyvanse, which has been the subject of two approvable letters from the FDA and is likely to get fully cleared shortly. |
Bristol-Myers Squibb |
Adnexus |
$240M development pact |
Bristol-Myers Squibb has committed to give Adnexus $30 million over the next three years and up to $210 million in milestones for each product developed in a new collaboration on new cancer therapies. |
Invitrogen |
Avista Capital |
$210 sale |
Invitrogen is selling its pharmaceutical services division, BioReliance, to Avista Capital for $210 million. |
Inspire Pharmaceuticals |
InSite Vision's |
$33M deal |
Inspire Pharmaceuticals has licensed the U.S. and Canadian commercialization rights to InSite Vision anti-infective AzaSite. |
Cepheid |
Altana |
$27M sale |
Cepheid is buying Sweden's Sangtec Molecular Diagnostics from Altana for about $27 million in cash. |
Optimer Pharma |
Par Pharmaceuticals |
$20M buy-back |
Optimer agreed to pay Par $20 million for the buy-back of Difimicin, which is in Phase IIb/III in North America. |
Pluristem |
Stem Cell Innovations |
Stock swap and licensing deal |
The licensing agreement provides Stem Cell with certain rights to Pluristem's PLX I product and 3-D stem cell expansion capability, in exchange for an upfront fee of 23 million shares of Stem Cell's common stock, milestone payments and royalties. |
Sartorius |
Stedim Biosystems |
Deal |
Germany's Sartorius has struck a deal to combine its biotech division with Stedim Biosystems. Sartorius emerges as the majority owner of a combined company called Sartorius Stedim Biotechnology. |